Platform of Science & Expertise

Preclinical Services

MD Biosciences AAALAC accredited Preclinical Services Laboratories provide exclusive, in-depth studies in the core areas of immunology, inflammatory diseases and neurology. Therapeutic areas include cancer, with particular focus on onco-immunology, joint, respiratory, gastrointestinal and skin inflammation, wound healing and metabolic studies. Pain and neurodegenerative diseases form the core of our strong CNS and neurological studies area. Studies are accompanied by a host of in vitro methodologies including multiplex protein analysis, qPCR, flow cytometry, histology and immunohistochemistry, offering the opportunity to investigate mode of action of candidate drugs.


CLIA Clinical Biomarker Diagnostic Laboratory

MD Biosciences provides its biomarker expertise through its CLIA Clinical Diagnostics laboratory, one of the few largest independent, regional, clinical laboratories in the upper midwest of the United States. Services include biomarker validation and assay development as well as proprietary cancer markers, specifically in the area of gastro-intestinal carcinomas. Services are rounded out with routine clinical chemistry, urinalysis and hematology analyses provided with same day turn-around of samples. Learn more about the services and what our laboratory can do for your studies and samples.


MD Biosciences Research Products

MD Biosciences develops monoclonal antibodies, proteins and assays through the course of its research. Such products are manufactured and provided for sale through our dedicated offices and representatives throughout the world. Discover our products including the ArthritoMAB® antibody cocktail for induction of arthritis, our bovine collagen products, Neurofreeze® for the preservation of neuronal cells, our unique anti-mouse IgD for the study of B-cell activation and many other exciting products.


Collaborative Drug Development

Learn about our emerging pipeline of lead compounds addressing unmet needs at the cross-section of inflammation and pain. Our pipeline includes lead, first-in-class, non-opioid compounds for the therapy of neuropathic and chronic pain as well as vectorized vaccine for canine osteosarcoma with its equivalent in development for human therapeutic applications. Collaborative activity is supported by InnovX®, the platform for taking nascent technologies from bench to lead status. Talk to us about our collaboration and investment possibilities.


Have Questions? Contact Us


MD Biosciences Announces License to Colorectal Cancer Markers

Oct 14, 2016 8:53:54 AM

MD Biosciences in-licenses intellectual property assets relating to colorectal cancer ... Read More

MD Biosciences to Present At 13th Int'l Neuroimmunology Congress

Sep 6, 2016 4:55:34 PM

St. Paul, Minn., September 6, 2016 - MD Biosciences announces its attendance at the 13th ... Read More

Upcoming Event

BioEurope 2016

November 7-9, 2016

Cologne, Germany